All In Biotech

NDA 204819 · Bayer Hlthcare

Adempas

Riociguat · Oral · Soluble Guanylate Cyclase Stimulator

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Oct 8, 2013

Approved uses

2

Original approval plus efficacy supplements

Registered trials

57

11 Phase 3, 5 recruiting

FAERS reports

32,879

25,172 serious, 7,129 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY Adempas is contraindicated for use during pregnancy because it may cause fetal harm based on animal data [see Contraindications (4.1) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1) ]. Exclude pregnancy prior to the start of treatment with Adempas. Advise use of effective contraception prior to initiation of treatment, during treatment, and for one month after treatment with Adempas [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.3) ]. If pregnancy is detected, discontinue Adempas as soon as possible [see Warnings and Precautions (5.1) ]. WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning Based on animal data, Adempas may cause fetal harm if used during pregnancy. ( 4.1 , 5.1 , 8.1 ) Exclude pregnancy before start of treatment Use...

What it is approved for

From the label in effect Aug 13, 2026.

Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. ( 1.1 ) • Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. ( 1.2 ) 1.1 Chronic-Thromboembolic Pulmonary Hypertension Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class [see Clinical Studies (14.1) ]. 1.2 Pulmonary Arterial Hypertension Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%) [see Clinical Studies (14.2) ] .

Mechanism: Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation. Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat has a dual mode of action. It...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • ADEMPAS · RIOCIGUAT 1MG · TABLET, ORAL · Prescription · TE AB
  • ADEMPAS · RIOCIGUAT 2.5MG · TABLET, ORAL · Prescription · TE AB
  • ADEMPAS · RIOCIGUAT 1.5MG · TABLET, ORAL · Prescription · TE AB
  • ADEMPAS · RIOCIGUAT 0.5MG · TABLET, ORAL · Prescription · TE AB
  • ADEMPAS · RIOCIGUAT 2MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Riociguat" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea5,794
  • death5,421
  • headache4,575
  • nausea3,819
  • dizziness3,589
  • diarrhoea3,574
  • hypotension3,452
  • fatigue3,021
  • hospitalisation2,326
  • vomiting2,147
  • cough1,827
  • oedema peripheral1,802

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20114
201210
201350
2014837
20151,491
20162,606
20172,909
20183,297
20193,075
20203,101
20212,953
20222,850
20232,902
20243,038
20252,363
20261,393

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Adempas (Riociguat)

2024 spending

$694M

Beneficiaries

5,553

50,847 claims

Per beneficiary

$125,022

$154.23 per unit

View as table
YearSpending
2020$463,152,406
2021$566,502,537
2022$576,981,088
2023$598,223,220
2024$694,246,753

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 85 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.